Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A

Lignende værker

• BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
  af: Santoro, Cristina, et al.
  Udgivet: (2020)
• BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review
  af: Mahlangu, Johnny N., et al.
  Udgivet: (2018)
• Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
  af: Solms, Alexander, et al.
  Udgivet: (2020)
• Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
  af: Pocoski, Jennifer, et al.
  Udgivet: (2016)
• Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81–8973 compared with other full-length rFVIII products
  af: Teare, John M, et al.
  Udgivet: (2019)